The FDA has released draft guidelines on how it intends to regulate expanded access to experimental drugs. The guidance on investigational new drug applications comes in a question-and-answer format; feedback is due by July 1.
Here’s a question -- How about FDA actually approving rare disease NDAs so patients have access for the long term. Giving medicines away for free is not a sustainable business model, nor allow development for the next generation of disease treatments.
Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.
